Assessment of Some Metabolic and Hematological Markers in Women Exposed to in Vitro Fertilization
1 other identifier
observational
115
0 countries
N/A
Brief Summary
Assisted reproductive technologies (ART) represent commonly utilized management strategies for infertility with multifactorial causes (including genetically predisposed diseases). Amongst ART, in vitro fertilization (IVF) is the most popular. IVF treatment may predispose the mother to increased risks and complications during pregnancy, and there may be adverse fetal outcomes. Hormonal therapies, including oral contraceptives, may impair glucose and lipid metabolism, and promote insulin resistance and inflammation. In vitro fertilization therapy induces weight gain and impairment in glucose, insulin and lipid homeostasis in failed IVF. Improvement of glucose homeostasis, decrease in thyroid profile and increase in lipid profile in clinical pregnancy are likely a pregnancy-related effect. Hyperglycemic pregnant women were proven to have a high prevalence of caesarean section, preterm delivery, low one-minute Apgar score, respiratory distress syndrome, neonatal jaundice, admission to the neonatal ICU, infants born large for gestational age (LGA), macrosomia.preconception abnormal glucose metabolism may increase the risk of adverse neonatal outcomes in PCOS women. The monitoring and management of preconception glucose homeostasis and IR are essential methods of improving the neonatal outcomes of PCOS women. Successful implantation and placentation require well-balanced inflammation and immune tolerance. Apart from white blood cells, the role of platelets in the release of mediators that cause local changes in the inflammatory process is very relevant. Increased levels of CBC inflammation markers may have a negative impact on IVF outcomes among nonobese women with UI. Successful embryo implantation requires a favorable endometrium, good-quality embryos and delicate coordination between the embryo and endometrium. The tightly controlled inflammatory response in the window of receptivity is essential for successful implantation and growing evidence suggests that chronic inflammation is associated with RIF. the aim of this study -To explore effects of IVF therapies on metabolic and endocrinal parameters in IVF-conceived pregnancy and its relation to outcome. 2- To investigate whether there could be an association between hematological infammatory markers and in vitro fertilization (IVF) success
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2025
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 3, 2025
CompletedFirst Posted
Study publicly available on registry
February 6, 2025
CompletedStudy Start
First participant enrolled
March 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2027
ExpectedFebruary 6, 2025
February 1, 2025
1 year
February 3, 2025
February 3, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in metabolic marker level
change in glucose levels during pregnancy period in IVF women
9 month
Study Arms (1)
IVF women
Women aged 30 years of age and above, presenting with any infertility concern and BMI 18.5-38 kg/m2.
Eligibility Criteria
Women aged 30 years of age and above, presenting with any infertility concern and BMI 18.5-38 kg/m2.
You may qualify if:
- Women aged 30 years of age and above,
- presenting with any infertility concern
- BMI 18.5-38 kg/m2
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- residdant doctor
Study Record Dates
First Submitted
February 3, 2025
First Posted
February 6, 2025
Study Start
March 1, 2025
Primary Completion
March 1, 2026
Study Completion (Estimated)
May 1, 2027
Last Updated
February 6, 2025
Record last verified: 2025-02